Dr.LeslieOBGYN said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.
Dr.LeslieOBGYN said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.
From the other side of the consultation, briefly.
Vendor communication red flags for compounded supply:
A legitimate compounding pharmacy operates like a healthcare business, not a gray market dealer.
james_edin said:SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1.
I read this differently from james_edin, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsnick_newbie said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide still in shortage, tirzepatide removed from shortage list. This directly impacts compounding availability.